A Phase 2 interventional study of Lebrikizumab and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Hoffmann-La Roche. Completed at 63 sites in 9 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche — 1 open to participants now, 2 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Hoffmann-La Roche.
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, this one is the only one that started in 2015, is one of 4 in phase 2, and was the 2nd registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United Kingdom
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 2
First in 2009; this study’s year is marked. 1 started in 2015.
This study's enrollment of 309 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 104 across the 9 interventional studies, 0 across the 1 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
1 of the studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase II, randomized, double-blind, placebo-controlled, parallel-group clinical trial of lebrikizumab in participants with COPD and a history of exacerbations who are treated with inhaled corticosteroid (ICS) and at least one long-acting bronchodilator inhaler medication. This study will be conducted to assess the safety, efficacy, and patient-reported outcome (PRO) measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
Drug: Lebrikizumab
Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
Drug: Lebrikizumab
Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
Drug: Placebo
Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
Drug: Placebo
Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.
Matching placebo will be administered subcutaneously once in every 4 weeks.
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Week 12
Adjusted mean change from baseline in pre-bronchodilator FEV1 (assessed using spirometry) at Week 12 was calculated.
Time frame: Baseline, Week 12
Rate of Moderate or Severe COPD Exacerbation
A moderate COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days that lead to treatment with systemic corticosteroids and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days that lead to hospitalization. Adjusted exacerbation rate per year was calculated. Results are reported as a 'Number' representing the unadjusted annualized rate of COPD exacerbations per person-year. The total number of exacerbations observed during the period was defined as starting at the date of randomization and ending at most 172 days after randomization (including data collected during safety follow-up in the case of early drug discontinuation) regardless of adherence to study drug divided by the total patient-weeks at risk divided by 52 weeks per year.
Time frame: Baseline up to Week 24
Change From Baseline in Post-bronchodilator FEV1 at Week 24
Adjusted mean change from baseline in post-bronchodilator FEV1 at Week 24 was calculated.
Time frame: Baseline, Week 24
Change From Baseline in Pre-bronchodilator FEV1 at Week 24
Adjusted mean change from baseline in pre-bronchodilator FEV1 at Week 24 was calculated.
Time frame: Baseline, Week 24
Time to First COPD Exacerbation
COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days. Time to first COPD exacerbation was estimated using Kaplan-Meier analysis.
Time frame: Baseline up to Week 24
Change From Baseline in Health-Related Quality of Life as Assessed by the Overall Score of the Saint George's Respiratory Questionnaire for COPD (SGRQ-C) at Week 24
SGRQ-C was assessed by asking participants to recall their COPD-related experiences and to respond to 40 questions included within three domains: symptoms (7 items), activity (13 items), and impacts (20 items). Overall SGRQ-C score ranged from 0 to 100, where lower score indicated better health-related quality of life. Change from baseline in overall SGRQ-C score at Week 24 was reported.
Time frame: Baseline, Week 24
Change From Baseline in COPD Symptoms as Measured by the Overall Score of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) at Week 24
EXACT comprised of 14-item questionnaire containing four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (3 items). Overall EXACT score was the average of domain scores. It ranged from 0 to 100, where higher score indicated a more severe condition. Change from baseline in overall EXACT score at Week 24 was reported.
Time frame: Baseline, Week 24
Change From Baseline in Cough and Sputum as Measured by the Cough and Sputum Domain Score of the EXACT at Week 24
EXACT comprised of 14-item questionnaire containing four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (3 items). Cough and Sputum domain score ranged from 0 to 100, where higher score indicated a more severe condition. Change from baseline in cough and sputum domain EXACT score at Week 24 was reported.
Time frame: Baseline, Week 24
Change From Baseline in Dyspnea as Assessed by the Baseline Dyspnea Index/Transition Dyspnea Index (BDI/TDI) at Week 24
The BDI scores ranged from 0 (very severe impairment) to 4 (no impairment) for each of 3 domains (functional impairment, magnitude of task, and magnitude of effort) and were summed to determine the BDI total score (0 to 12). The TDI scores ranged from -3 (major deterioration) to +3 (major improvement) for each of the 3 domains (functional impairment, magnitude of task, and magnitude of effort). The sum of all domains yielded the TDI total score (-9 to +9). Change from baseline in BDI/TDI at Week 24 was reported.
Time frame: Baseline, Week 24
Percentage of Participants With Anti-Therapeutic Antibody (ATA) to Lebrikizumab
This outcome measure was planned to be analyzed only in overall lebrikizumab arm.
Time frame: Baseline up to Week 36
Minimum Observed Serum Trough Concentration (Cmin) of Lebrikizumab
This outcome measure was planned to be analyzed only in overall lebrikizumab arm.
Time frame: Pre-dose (Hour 0) at Weeks 4 and 12, at Week 24
Elimination Half-Life (t1/2) of Lebrikizumab
Elimination half-life was defined as the time measured for the serum concentration to decrease by one half. This outcome measure was planned to be analyzed only in overall lebrikizumab arm.
Time frame: Pre-dose (Hour 0) on Day 1 (Baseline) and Weeks 1, 4, 12, 24, 28, and 36
| Milestone | Placebo | Lebrikizumab |
|---|---|---|
| Started | 154 | 155 |
| Completed | 144 | 146 |
| Not completed | 10 | 9 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 8 | 2 |
Adjusted mean change from baseline in pre-bronchodilator FEV1 (assessed using spirometry) at Week 12 was calculated.
| milliliters (mL) | Placebo: Biomarker-High | Lebrikizumab: Biomarker-High | Placebo: Biomarker-Low | Lebrikizumab: Biomarker-Low |
|---|---|---|---|---|
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Week 12 | 46.4 (1.5 to 91.2) | 51.7 (8.2 to 95.1) | -20.1 (-68.0 to 27.8) | -8.1 (-56.8 to 40.5) |
A moderate COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days that lead to treatment with systemic corticosteroids and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days that lead to hospitalization. Adjusted exacerbation rate per year was calculated. Results are reported as a 'Number' representing the unadjusted annualized rate of COPD exacerbations per person-year. The total number of exacerbations observed during the period was defined as starting at the date of randomization and ending at most 172 days after randomization (including data collected during safety follow-up in the case of early drug discontinuation) regardless of adherence to study drug divided by the total patient-weeks at risk divided by 52 weeks per year.
| exacerbations per person-year | Placebo: Biomarker-High | Lebrikizumab: Biomarker-High | Placebo: Biomarker-Low | Lebrikizumab: Biomarker-Low |
|---|---|---|---|---|
| Rate of Moderate or Severe COPD Exacerbation | 0.78 | 1.07 | 0.93 | 1.14 |
Adjusted mean change from baseline in post-bronchodilator FEV1 at Week 24 was calculated.
| mL | Placebo: Biomarker-High | Lebrikizumab: Biomarker-High | Placebo: Biomarker-Low | Lebrikizumab: Biomarker-Low |
|---|---|---|---|---|
| Change From Baseline in Post-bronchodilator FEV1 at Week 24 | 20.6 (-24.5 to 65.6) | 31.2 (-12.0 to 74.5) | -8.3 (-56.5 to 39.9) | -10.7 (-60.2 to 38.8) |
Adjusted mean change from baseline in pre-bronchodilator FEV1 at Week 24 was calculated.
| mL | Placebo: Biomarker-High | Lebrikizumab: Biomarker-High | Placebo: Biomarker-Low | Lebrikizumab: Biomarker-Low |
|---|---|---|---|---|
| Change From Baseline in Pre-bronchodilator FEV1 at Week 24 | 17.5 (-26.4 to 61.5) | 46.8 (4.3 to 89.3) | -31.4 (-78.3 to 15.5) | 1.9 (-46.1 to 49.9) |
COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days. Time to first COPD exacerbation was estimated using Kaplan-Meier analysis.
| days | Placebo: Biomarker-High | Lebrikizumab: Biomarker-High | Placebo: Biomarker-Low | Lebrikizumab: Biomarker-Low |
|---|---|---|---|---|
| Time to First COPD Exacerbation | NA (NA to NA) | 25.9 (24.9 to NA) | NA (25.0 to NA) | 24.9 (24.0 to NA) |
SGRQ-C was assessed by asking participants to recall their COPD-related experiences and to respond to 40 questions included within three domains: symptoms (7 items), activity (13 items), and impacts (20 items). Overall SGRQ-C score ranged from 0 to 100, where lower score indicated better health-related quality of life. Change from baseline in overall SGRQ-C score at Week 24 was reported.
| units on a scale | Placebo: Biomarker-High | Lebrikizumab: Biomarker-High | Placebo: Biomarker-Low | Lebrikizumab: Biomarker-Low |
|---|---|---|---|---|
| Change From Baseline in Health-Related Quality of Life as Assessed by the Overall Score of the Saint George's Respiratory Questionnaire for COPD (SGRQ-C) at Week 24 | -5.4 (-8.3 to -2.4) | -4.6 (-7.5 to -1.7) | -8.8 (-11.9 to -5.7) | -2.4 (-5.6 to 0.9) |
EXACT comprised of 14-item questionnaire containing four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (3 items). Overall EXACT score was the average of domain scores. It ranged from 0 to 100, where higher score indicated a more severe condition. Change from baseline in overall EXACT score at Week 24 was reported.
| units on a scale | Placebo: Biomarker-High | Lebrikizumab: Biomarker-High | Placebo: Biomarker-Low | Lebrikizumab: Biomarker-Low |
|---|---|---|---|---|
| Change From Baseline in COPD Symptoms as Measured by the Overall Score of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) at Week 24 | -2.4 (-4.4 to -0.4) | -2.4 (-4.5 to -0.3) | -1.9 (-4.2 to 0.4) | -1.4 (-3.7 to 1.0) |
EXACT comprised of 14-item questionnaire containing four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (3 items). Cough and Sputum domain score ranged from 0 to 100, where higher score indicated a more severe condition. Change from baseline in cough and sputum domain EXACT score at Week 24 was reported.
| units on a scale | Placebo: Biomarker-High | Lebrikizumab: Biomarker-High | Placebo: Biomarker-Low | Lebrikizumab: Biomarker-Low |
|---|---|---|---|---|
| Change From Baseline in Cough and Sputum as Measured by the Cough and Sputum Domain Score of the EXACT at Week 24 | -4.0 (-6.9 to -1.2) | -5.2 (-8.2 to -2.2) | -5.6 (-8.9 to -2.3) | -2.2 (-5.7 to 1.2) |
The BDI scores ranged from 0 (very severe impairment) to 4 (no impairment) for each of 3 domains (functional impairment, magnitude of task, and magnitude of effort) and were summed to determine the BDI total score (0 to 12). The TDI scores ranged from -3 (major deterioration) to +3 (major improvement) for each of the 3 domains (functional impairment, magnitude of task, and magnitude of effort). The sum of all domains yielded the TDI total score (-9 to +9). Change from baseline in BDI/TDI at Week 24 was reported.
| ratio | Placebo: Biomarker-High | Lebrikizumab: Biomarker-High | Placebo: Biomarker-Low | Lebrikizumab: Biomarker-Low |
|---|---|---|---|---|
| Change From Baseline in Dyspnea as Assessed by the Baseline Dyspnea Index/Transition Dyspnea Index (BDI/TDI) at Week 24 | 1.0 ± 2.9 | 1.4 ± 2.9 | 2.3 ± 2.8 | 1.6 ± 3.3 |
This outcome measure was planned to be analyzed only in overall lebrikizumab arm.
| percentage of participants | Lebrikizumab |
|---|---|
| Percentage of Participants With Anti-Therapeutic Antibody (ATA) to Lebrikizumab | 13.6 |
This outcome measure was planned to be analyzed only in overall lebrikizumab arm.
| micrograms per milliliter (mcg/mL) | Lebrikizumab |
|---|---|
| Week 4 | 9.09 ± 3.64 |
| Week 12 | 14.7 ± 6.68 |
| Week 24 | 15.2 ± 8.10 |
Elimination half-life was defined as the time measured for the serum concentration to decrease by one half. This outcome measure was planned to be analyzed only in overall lebrikizumab arm.
| days | Lebrikizumab |
|---|---|
| Elimination Half-Life (t1/2) of Lebrikizumab | 25.1 ± 7.26 |
Collected over Baseline up to Week 36. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 2/154 (1.3%) | 23/154 (14.9%) | 66/154 (42.9%) |
| Lebrikizumab | 1/155 (0.6%) | 21/155 (13.5%) | 57/155 (36.8%) |
| Event | Placebo | Lebrikizumab |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 10/154 | 15/155 |
| PneumoniaInfections and infestations | 3/154 | 3/155 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/154 | 1/155 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 1/154 | 0/155 |
| Pulmonary necrosisRespiratory, thoracic and mediastinal disorders | 1/154 | 0/155 |
| Respiratory arrestRespiratory, thoracic and mediastinal disorders | 1/154 | 0/155 |
| DiverticulitisInfections and infestations | 1/154 | 0/155 |
| InfluenzaInfections and infestations | 1/154 | 0/155 |
| Atrial fibrillationCardiac disorders | 1/154 | 0/155 |
| Coronary artery occlusionCardiac disorders | 1/154 | 0/155 |
| Event | Placebo | Lebrikizumab |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 55/154 | 51/155 |
| BronchitisInfections and infestations | 10/154 | 9/155 |
| NasopharyngitisInfections and infestations | 7/154 | 7/155 |
Modified intent-to-treat (mITT) population: all participants who received at least one dose of study treatment, grouped according to the treatment assigned at randomization.
| Age, Continuous(years) | Placebo | Lebrikizumab | Total |
|---|---|---|---|
| Mean | 64.6 ± 7.1 | 64.5 ± 7.1 | 64.5 ± 7.1 |
| Sex: Female, Male(Participants) | Placebo | Lebrikizumab | Total |
|---|---|---|---|
| Female | 58 | 58 | 116 |
| Male | 96 | 97 | 193 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Lebrikizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 14 | 27 |
| Not Hispanic or Latino | 141 | 140 | 281 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | Lebrikizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 4 | 12 |
| White | 142 | 147 | 289 |
| More than one race | 3 | 2 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Nov 2016, 14 months.
Results were first posted in Sep 2026, 9 years 9 months after primary completion.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 14 months is close to that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab
Pulmonary Disease, Chronic Obstructive →